publication date: Jun. 2, 2016

Melanoma

Phase Ib Trial Shows 40 Percent of Patients Receiving Keytruda Alive After 36-Month Follow Up

 

Long-term follow-up from a phase Ib trial in newly diagnosed and previously treated patients with advanced melanoma showed that 40 percent of patients were alive three years after starting Keytruda (pembrolizumab), with similar 36-month overall survival rates in both groups.

The study, KEYNOTE-001, will be presented at the annual meeting of the American Society of Clinical Oncology.

Keytruda received accelerated approval from FDA in September 2014 for the treatment of advanced melanoma, based on data from KEYNOTE-001. Additional clinical studies, KEYNOTE-002 and KEYNOTE-006, have also shown a survival benefit with Keytruda in patients with advanced melanoma when compared with chemotherapy or Yervoy (ipilimumab), according to ASCO. Keytruda, a PD-1 inhibitor, is sponsored by Merck, which funded KEYNOTE-001.

Fifteen percent of patients in this study experienced complete remissions according to immune-related response criteria. Of these patients, 89 percent remain in remission.

The study included 655 patients diagnosed with advanced melanoma. Seventy-five percent of patients had previously received other treatments, including Yervoy. Study participants received … Continue reading CCL May – Melanoma Phase Ib Trial Shows 40 Percent of Patients Receiving Keytruda Alive After 36-Month Follow Up

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.